Ability to Stabilise and Stockpile Covid-19 Vaccine is Vital
WHO estimate 50% of vaccines are wasted due to refrigeration failure
Breakthrough Invention StablevaX™ Eradicates Refrigeration Need – An Essential Partner for Vaccine Manufacturers
Bath, UK, 2 April 2020
A British breakthrough invention could form a crucial part in the urgent quest to combat Covid-19 and future virus pandemics. StablevaX™ allows vaccines to be transported and stored for years in a syringe without refrigeration, a unique capability.
Currently, the World Health Organisation (WHO) estimates that 50% of the world’s vaccines are rendered ineffective due to failings in the delivery and storage refrigeration processes, known as the ‘The Cold Chain’. The breakthrough will enable countries to confidently stockpile vaccinations that can be instantly injected, ultimately saving lives.
The current candidates for a Covid-19 vaccine include re-purposed drugs; established antivirals; monoclonal antibodies; non-specific therapeutics and new vaccines in development such as recombinant live virus vectors. StablevaX™ has been shown to thermally stabilise examples of all these classes of product, while complying with the vaccination protocols set by the WHO.
“We have investigated the current candidates for a Covid-19 vaccine and believe that our technology would be highly beneficial in the fight against the Covid-19 pandemic. A breakthrough and potential game changer, StablevaX™ provides a solution that eradicates the reliance on the cold chain and enables vaccine stockpiling anywhere in the world. Stablepharma stands ready to make our technologies widely available in the global fight against the Covid-19 pandemic by partnering with vaccine manufacturers to save many lives.” says Stablepharma Managing Director and Founder, Nick Child.
Stablepharma uses trehalose to stabilise pre-approved vaccines by drying the correct dose inside a special sponge and housing the sponge in a normal syringe. The result is an instantly injectable life-saving vaccine, at the correct dose, that can be stored on a shelf in just about any climate. Notoriously unstable naked RNA is uniquely rendered stable at c. 45°C.
Over 50 pharmaceutical, biotechnology and R&D products stabilised in this way show extreme thermal stability measured in years at high temperatures >45 ⁰ C. Live virus vectors such as Adenovirus and MVA poxvirus can be rendered stable for many months.
The huge benefit of StablevaX™ will be its unique ability to enable vaccines to be delivered and even stockpiled in the most inhospitable parts of the world, negating the expensive and unreliable ‘cold chain’ and thereby allowing vaccines to reach everyone, everywhere.
Note to Editor:
How StablevaX™ Works – 54 sec. video: https://vimeo.com/343041802
StablevaX Introduction by Dr. Bruce Roser MB BS, PhD, FRCPA
The StablevaX invention is the culmination of over 30 years of my work on the preservation of biological molecules. I first learned that biological molecules could be completely preserved in hostile conditions by reading of the many rare creatures, from bacteria to plants that had the miraculous ability to dry out during a drought and die, yet come back to life when it rained!
Being blessed with total ignorance, I guessed that there may be a common feature in all these different species. It turned out that many contained large amounts of a sugar I had never heard of – Trehalose. So, working with some very unstable molecules in the lab like vaccines, that also required constant refrigeration, I did a few simple experiments. Everything I tried was completely undamaged when dried with trehalose. EUREKA!
I have since used trehalose to stabilise many vaccines and drugs and I have learned enough to know that trehalose can be used in simple ways to give startling results. I then patented the technology which enables vaccines to be kept in a box in the shelf for years without losing potency and then instantly injected. You can see it in action in our short video:
Stablepharma – The Story behind the Invention: https://vimeo.com/327997696
Stablepharma have patented a ground-breaking invention to improve healthcare for those most at risk of death and disability caused by vaccine preventable diseases
Stablepharma’s vision is to eliminate the need for refrigeration, provide expanded access to children and adults who are most at need of vaccines in developing countries and eradicate the costs of the ‘Cold Chain’, globally estimated to be $400m each year
Zero refrigeration = eliminates waste = saves more lives
Owing to Dr Bruce Roser’s dedication and extensive research, Stablepharma is bringing to market a disruptive process to eradicate vaccine wastage, reduce costs and more importantly, stabilise lifesaving vaccines.
The huge benefit of StablevaX™ will be its unique ability to enable vaccines to be stored in even the most inhospitable parts of the world, negating the expensive and unreliable ‘Cold Chain’ and thereby allowing vaccines to reach everyone, everywhere.
For further information:
Nick Child, Managing Director & Founder, Stablepharma